利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.037 秒)

    Anti-pancreatic cancer antibodies
    3.
    发明授权
    Anti-pancreatic cancer antibodies 有权
    抗胰腺癌抗体

    公开(公告)号：US08974784B2

    公开(公告)日：2015-03-10

    申请号：US14274960

    申请日：2014-05-12

    申请人： Immunomedics, Inc.

    发明人： David M. Goldenberg ,  Hans J. Hansen ,  Chien-Hsing Chang ,  David V. Gold

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39558 ,  A61K51/1057 ,  A61K51/1093 ,  A61K51/1096 ,  A61K2039/505 ,  C07K16/2887 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  A61K2300/00

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.

    摘要翻译： 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 受试抗体显示出许多新颖有用的治疗特征，例如对胰腺癌和其他癌症具有高度特异性的结合，但不与正常或良性胰腺组织结合并结合高百分比的早期胰腺癌。 在优选的实施方案中，抗体结合胰腺癌粘蛋白。 抗体和片段可用于癌症如胰腺癌的检测，诊断和/或治疗。 与其他已知抗体（例如CA19.9，DUPAN2，SPAN1，Nd2，B72.3和Lea和Le（y））抗体相比，抗体如PAM4抗体与PAM4抗原结合，其显示独特的细胞和组织分布， 结合Lewis抗原。

    Detection of Early-Stage Pancreatic Adenocarcinoma
    4.
    发明申请
    Detection of Early-Stage Pancreatic Adenocarcinoma 审中-公开
    早期胰腺腺癌的检测

    公开(公告)号：US20170035908A1

    公开(公告)日：2017-02-09

    申请号：US15336106

    申请日：2016-10-27

    申请人： Immunomedics, Inc.

    发明人： David V. Gold ,  David M. Goldenberg

    IPC分类号： A61K47/48 ,  A61K49/00 ,  C07K16/44 ,  A61K51/10

    CPC分类号： A61K47/48746 ,  A61K47/6897 ,  A61K49/0058 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1018 ,  A61K51/109 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  G01N33/57438 ,  G01N33/57488 ,  G01N2333/4725

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

    摘要翻译： 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 受试抗体显示出许多新颖且有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不与正常胰腺组织结合并结合高百分比的早期胰腺癌。 在优选的实施方案中，抗体结合胰腺癌粘蛋白。 抗体和片段可用于早期胰腺癌的检测和诊断。 在优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定可检测血清中早期胰腺癌的标志物。 更优选地，在免疫测定之前，用有机相如丁醇萃取血清。

    Detection of Early-Stage Pancreatic Adenocarcinoma
    5.
    发明申请
    Detection of Early-Stage Pancreatic Adenocarcinoma 有权
    早期胰腺腺癌的检测

    公开(公告)号：US20160069885A1

    公开(公告)日：2016-03-10

    申请号：US14944993

    申请日：2015-11-18

    申请人： Immunomedics, Inc.

    发明人： David V. Gold ,  David M. Goldenberg

    IPC分类号： G01N33/574

    CPC分类号： A61K47/48746 ,  A61K47/6897 ,  A61K49/0058 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1018 ,  A61K51/109 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  G01N33/57438 ,  G01N33/57488 ,  G01N2333/4725

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

    摘要翻译： 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 受试抗体显示出许多新颖且有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不与正常胰腺组织结合并结合高百分比的早期胰腺癌。 在优选的实施方案中，抗体结合胰腺癌粘蛋白。 抗体和片段可用于早期胰腺癌的检测和诊断。 在优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定可检测血清中早期胰腺癌的标志物。 更优选地，在免疫测定之前，用有机相如丁醇萃取血清。

    Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer
    6.
    发明申请
    Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer 审中-公开
    抗粘蛋白抗体用于早期检测和治疗胰腺癌

    公开(公告)号：US20150320872A1

    公开(公告)日：2015-11-12

    申请号：US14744290

    申请日：2015-06-19

    申请人： Immunomedics, Inc.

    发明人： David V. Gold ,  David M. Goldenberg

    IPC分类号： A61K47/48 ,  A61K51/10 ,  C07K16/30

    CPC分类号： A61K47/486 ,  A61K47/6897 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/109 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/57438 ,  G01N33/6854 ,  G01N2333/4725 ,  G01N2800/52

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

    摘要翻译： 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 抗体显示出新的和有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不对正常或良性胰腺组织结合并结合高百分比的早期胰腺癌。 优选地，抗体结合胰腺癌粘蛋白如MUC1或MUC5ac，并且可用于早期胰腺癌的检测和诊断。 在更优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定检测血清中早期胰腺癌的标志物。 最优选地，在免疫测定之前，用有机相如丁醇萃取血清。 或者，可以使用具有PAM4和抗CA19.9抗体的免疫测定来提高胰腺癌的敏感性。

    Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer
    8.
    发明申请
    Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer 有权
    抗粘蛋白抗体用于早期检测和治疗胰腺癌

    公开(公告)号：US20140112864A1

    公开(公告)日：2014-04-24

    申请号：US14036765

    申请日：2013-09-25

    申请人： Immunomedics, Inc.

    发明人： David V. Gold ,  David M. Goldenberg

    IPC分类号： A61K51/10 ,  G01N33/68

    CPC分类号： A61K47/486 ,  A61K47/48569 ,  A61K47/48746 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6897 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/109 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6854

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

    摘要翻译： 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 抗体显示出新的和有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不对正常或良性胰腺组织结合并结合高百分比的早期胰腺癌。 优选地，抗体结合胰腺癌粘蛋白如MUC1或MUC5ac，并且可用于早期胰腺癌的检测和诊断。 在更优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定检测血清中早期胰腺癌的标志物。 最优选地，在免疫测定之前，用有机相如丁醇萃取血清。 或者，可以使用具有PAM4和抗CA19.9抗体的免疫测定来提高胰腺癌的敏感性。